Practical management of patients with IDH-mutant glioma in the coming era of mIDH inhibitors: New drugs, new evidence, new guidelines, and new considerations
Neurooncol Pract
.
2024 Oct 19;12(Suppl 1):i2-i5.
doi: 10.1093/nop/npae076.
eCollection 2025 Feb.
Authors
Katherine B Peters
1
,
Marjolein Geurts
2
Affiliations
1
Department of Neurosurgery, Duke University Medical Center, USA.
2
Department of Neurology, Erasmus MC, Rotterdam, The Netherlands.
PMID:
39776529
PMCID:
PMC11703364
(available on
2025-10-19
)
DOI:
10.1093/nop/npae076
No abstract available
Keywords:
glioma; inhibitor; isocitrate dehydrogenase; mutant.
Publication types
Review